N@N

Curis to Present at RBC Capital Markets 2008 Healthcare Conference

^{Published on 2008-12-07 07:36:15 - Market Wire}
 

CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be participating in the RBC Capital Markets 2008 Healthcare Conference. Dan Passeri, Curis' President and Chief Executive Officer, will participate in a panel entitled "Building A Pipeline Of Partnered And Proprietary Drugs" on Thursday, December 11, 2008 from 10:00 a.m. until 10:55 a.m. EST at the Westin Times Square Hotel in New York, New York. The panel will be moderated by Jason Kantor, RBC Senior Biotechnology Analyst.

There will also be a corresponding webcast of the panel discussion, which can be accessed by visiting:

[ http://www.wsw.com/webcast/rbc95/panel22/ ]

The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will also be available for 30 days on the Investor Relations section of the Curis website at [ www.curis.com ].

About Curis, Inc.

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its proprietary targeted cancer programs, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at [ www.curis.com ].